Astex Therapeutics Grants Cytochrome P450 License To Pfizer Inc.

CB4 0WE, UK--(MARKET WIRE)--Jan 24, 2006 -- * Astex continues to strategically leverage its Cytochrome P450 intellectual property through a non-exclusive licensing agreement with Pfizer. The action of these enzymes is the cause of adverse drug reactions to many marketed drugs and drug-combination therapies and many failures of novel drugs during their development have been attributed to their interactions with this class of enzymes.

MORE ON THIS TOPIC